CA2778171C - Bridged artificial nucleoside and nucleotide - Google Patents

Bridged artificial nucleoside and nucleotide Download PDF

Info

Publication number
CA2778171C
CA2778171C CA2778171A CA2778171A CA2778171C CA 2778171 C CA2778171 C CA 2778171C CA 2778171 A CA2778171 A CA 2778171A CA 2778171 A CA2778171 A CA 2778171A CA 2778171 C CA2778171 C CA 2778171C
Authority
CA
Canada
Prior art keywords
group
carbon atoms
compound
amino
substituents selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2778171A
Other languages
English (en)
French (fr)
Other versions
CA2778171A1 (en
Inventor
Satoshi Obika
Yoshiyuki Hari
Tetsuya Kodama
Aiko Yahara
Masaru Nishida
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Osaka NUC
Original Assignee
Osaka University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osaka University NUC filed Critical Osaka University NUC
Publication of CA2778171A1 publication Critical patent/CA2778171A1/en
Application granted granted Critical
Publication of CA2778171C publication Critical patent/CA2778171C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/173—Purine radicals with 2-deoxyribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H23/00—Compounds containing boron, silicon or a metal, e.g. chelates or vitamin B12
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/51—Methods for regulating/modulating their activity modulating the chemical stability, e.g. nuclease-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2778171A 2009-10-29 2010-10-19 Bridged artificial nucleoside and nucleotide Active CA2778171C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2009248979 2009-10-29
JP2009-248979 2009-10-29
JP2010023209 2010-02-04
JP2010-023209 2010-02-04
PCT/JP2010/068409 WO2011052436A1 (ja) 2009-10-29 2010-10-19 架橋型人工ヌクレオシドおよびヌクレオチド

Publications (2)

Publication Number Publication Date
CA2778171A1 CA2778171A1 (en) 2011-05-05
CA2778171C true CA2778171C (en) 2017-07-25

Family

ID=43921860

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2778171A Active CA2778171C (en) 2009-10-29 2010-10-19 Bridged artificial nucleoside and nucleotide

Country Status (7)

Country Link
US (1) US8541562B2 (cg-RX-API-DMAC7.html)
EP (1) EP2495248B1 (cg-RX-API-DMAC7.html)
JP (2) JPWO2011052436A1 (cg-RX-API-DMAC7.html)
CN (1) CN102596983B (cg-RX-API-DMAC7.html)
AU (1) AU2010312751B2 (cg-RX-API-DMAC7.html)
CA (1) CA2778171C (cg-RX-API-DMAC7.html)
WO (1) WO2011052436A1 (cg-RX-API-DMAC7.html)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012029870A1 (ja) * 2010-08-31 2012-03-08 国立大学法人大阪大学 オリゴヌクレオチド、およびオリゴヌクレオチドを有効成分として含有する脂質異常症治療剤
US20140323709A1 (en) 2011-12-12 2014-10-30 National Cerebral And Cardiovascular Center Oligonucleotide and therapeutic agent for hyperlipidemia containing same as active ingredient
TW201402594A (zh) 2012-06-18 2014-01-16 Daiichi Sankyo Co Ltd 核苷類似物的製造中間體及其製造方法
CA2885719C (en) * 2012-09-21 2017-07-11 Osaka University Oligonucleotide and artificial nucleoside having guanidine bridge
WO2014109384A1 (ja) * 2013-01-10 2014-07-17 塩野義製薬株式会社 架橋型核酸誘導体の製造方法
JPWO2014112463A1 (ja) * 2013-01-15 2017-01-19 国立大学法人大阪大学 スルホンアミド構造を有するヌクレオシドおよびヌクレオチド
WO2014126229A1 (ja) 2013-02-18 2014-08-21 塩野義製薬株式会社 含窒素複素環構造を有するヌクレオシド及びヌクレオチド
WO2015020194A1 (ja) * 2013-08-09 2015-02-12 国立大学法人大阪大学 Ａｃｓｌ１に対するアンチセンスオリゴヌクレオチド
GB201410693D0 (en) 2014-06-16 2014-07-30 Univ Southampton Splicing modulation
US20170211073A1 (en) * 2014-07-10 2017-07-27 Kenji Nakano Antisense antineoplastic agent
KR102620328B1 (ko) 2014-10-03 2024-01-02 콜드스프링하버러보러토리 핵 유전자 산출량의 표적화 증강
JP2018140938A (ja) * 2015-07-24 2018-09-13 日産化学株式会社 人工ヌクレオシド及び人工ヌクレオチド並びに人工オリゴヌクレオチド
TW201718618A (zh) * 2015-09-18 2017-06-01 田邊三菱製藥股份有限公司 架橋型核酸ＧｕＮＡ，其製造方法，及中間體化合物
KR20220105174A (ko) 2015-10-09 2022-07-26 유니버시티 오브 사우스앰톤 유전자 발현의 조절 및 탈조절된 단백질 발현의 스크리닝
CN109312343B (zh) 2015-12-14 2022-09-27 冷泉港实验室 用于治疗常染色体显性精神发育迟滞5型和Dravet综合征的反义寡聚体
US11096956B2 (en) 2015-12-14 2021-08-24 Stoke Therapeutics, Inc. Antisense oligomers and uses thereof
EP3415524A4 (en) * 2016-01-07 2019-09-04 Osaka University INHIBITOR OF α-SYNNUCLEINE EXPRESSION
AU2017211461B2 (en) 2016-01-26 2023-01-12 Nissan Chemical Corporation Single-stranded oligonucleotide
EP3418289A4 (en) 2016-02-17 2019-10-30 Tokyo Institute of Technology ARTIFICIAL NUCLEOSIDE AND ARTIFICIAL NUCLEOTIDE AND ARTIFICIAL OLIGONUCLEOTIDE
WO2018009466A1 (en) 2016-07-05 2018-01-11 Aduro Biotech, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
JP2020055750A (ja) * 2017-01-30 2020-04-09 賢二 中野 癌浸潤または転移阻害核酸薬
CA3052801A1 (en) 2017-02-06 2018-08-09 Nissan Chemical Corporation Single-stranded oligonucleotide
WO2018155450A1 (ja) 2017-02-21 2018-08-30 国立大学法人大阪大学 アンチセンスオリゴ核酸
JP7138349B2 (ja) * 2017-02-21 2022-09-16 国立大学法人大阪大学 核酸化合物およびオリゴヌクレオチド
US11638717B2 (en) 2017-03-29 2023-05-02 Shionogi & Co., Ltd. Complex of nucleic acid medicine and multibranched lipid
JP7141621B2 (ja) 2017-03-31 2022-09-26 学校法人 愛知医科大学 コンドロイチン硫酸生合成を阻害するアンチセンス核酸
EP3633036A4 (en) 2017-05-26 2021-03-17 National Cerebral and Cardiovascular Center NUCLEIC ACID TARGETING ANTI-SENSES PCSK9
EP3628737A4 (en) 2017-07-05 2021-01-20 Osaka University ENA-ANTISENSE-OLIGONUCLEOTIDE TO INHIBIT ALPHA-SYNUCLEIN EXPRESSION
WO2019009298A1 (ja) * 2017-07-05 2019-01-10 国立大学法人大阪大学 α－シヌクレイン発現抑制剤
AU2018307294B2 (en) 2017-07-26 2025-04-17 Nissan Chemical Corporation Single-stranded oligonucleotide
SMT202400071T1 (it) 2017-08-25 2024-03-13 Stoke Therapeutics Inc Oligomeri antisenso per il trattamento di condizioni e malattie
JP7177446B2 (ja) 2017-08-31 2022-11-24 田辺三菱製薬株式会社 Ｉｌ－３３アンタゴニストを含む子宮内膜症治療剤
AU2019237599A1 (en) 2018-03-20 2020-11-12 Nissan Chemical Corporation Antisense oligonucleotide having reduced toxicity
US12060558B2 (en) 2018-05-04 2024-08-13 Stoke Therapeutics, Inc. Methods and compositions for treatment of cholesteryl ester storage disease
CN112513062B (zh) * 2018-07-31 2024-05-10 国立大学法人大阪大学 含有寡聚核苷酸的小细胞肺癌治疗药
EP3967328A4 (en) 2019-03-29 2022-12-28 Sysmex Corporation NEW ARTIFICIAL NUCLEIC ACID, METHOD FOR MAKING IT, AND USE THEREOF
SG11202112741XA (en) 2019-05-31 2021-12-30 Aligos Therapeutics Inc Modified gapmer oligonucleotides and methods of use
EP4005602A4 (en) 2019-07-30 2024-06-12 Shionogi & Co., Ltd NUCLEIC ACID AGENT TARGETED AGAINST MURF1
WO2021039879A1 (ja) 2019-08-27 2021-03-04 国立大学法人東海国立大学機構 胃癌分子標的核酸医薬
WO2021127406A1 (en) * 2019-12-19 2021-06-24 The Regents Of The University Of California Methods of producing target capture nucleic acids
WO2021132648A1 (ja) * 2019-12-27 2021-07-01 ルクサナバイオテク株式会社 Ｒｅｃｑｌの発現を阻害するアンチセンスオリゴヌクレオチド及びその用途
WO2021177267A1 (ja) 2020-03-02 2021-09-10 田辺三菱製薬株式会社 ｍｉＲ－３３ｂ阻害物質による動脈瘤の予防または治療
CN115485381A (zh) 2020-03-26 2022-12-16 国立研究开发法人国立循环器病研究中心 以apoc3为靶点的反义核酸
WO2021216785A1 (en) 2020-04-21 2021-10-28 Flagship Pioneering, Inc. Bifunctional molecules and methods of using thereof
CA3173647A1 (en) 2020-05-11 2021-11-18 Isabel AZNAREZ Opa1 antisense oligomers for treatment of conditions and diseases
EP4219517A4 (en) 2020-09-25 2024-09-25 Riken Genesis Co., Ltd. NOVEL ARTIFICIAL NUCLEIC ACID, METHOD FOR PRODUCING THE SAME AND USE THEREOF
WO2022097727A1 (ja) 2020-11-06 2022-05-12 住友ファーマ株式会社 Ｒｐｓ２５遺伝子の発現及び／又は機能調節剤
WO2022181807A1 (ja) 2021-02-25 2022-09-01 国立大学法人大阪大学 ＲＥＳＴ ｍＲＮＡ前駆体のプロセシングにおけるＮエキソンのスキッピングを誘導するオリゴヌクレオチド
EP4331606A4 (en) 2021-04-30 2025-05-07 Kyoto University PREVENTION OR TREATMENT OF MYOPATHY USING A MIR-33B INHIBITOR
US20240247263A1 (en) 2021-05-06 2024-07-25 Luxna Biotech Co., Ltd. Method for designing oligonucleotide having reduced central toxicity
KR20240013202A (ko) 2021-05-28 2024-01-30 스미토모 파마 가부시키가이샤 안티센스 핵산
EP4389893A4 (en) 2021-08-21 2025-09-10 Takeda Pharmaceuticals Co PEPTIDE-DRUG CONJUGATE BINDING HUMAN TRANSFERRIN RECEPTOR
JPWO2023127857A1 (cg-RX-API-DMAC7.html) 2021-12-27 2023-07-06
EP4495242A1 (en) 2022-03-17 2025-01-22 Aichi Medical University Antisense nucleic acid capable of inhibiting biosynthesis of chondroitin sulfate
CN120187739A (zh) 2022-11-10 2025-06-20 璐库萨那生物技术株式会社 桥联部具有胍基结构的修饰核苷和使用其的寡核苷酸的制造方法
JPWO2024181416A1 (cg-RX-API-DMAC7.html) 2023-02-28 2024-09-06
WO2024257847A1 (ja) 2023-06-16 2024-12-19 住友ファーマ株式会社 Ｒｐｓ２５遺伝子の発現及び／又はその機能を調節するアンチセンスオリゴヌクレオチド
WO2025005265A1 (ja) * 2023-06-30 2025-01-02 日産化学株式会社 毒性が低減されたアンチセンスオリゴヌクレオチド
US20250368996A1 (en) 2024-05-14 2025-12-04 Aligos Therapeutics, Inc. Modified antisense oligonucleotides for treating hepatitis b virus

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
HRP20000751A2 (en) 1998-05-26 2001-12-31 Icn Pharmaceuticals Novel nucleosides having bicyclic sugar moiety
US7615619B2 (en) 2002-02-13 2009-11-10 Takeshi Imanishi Nucleoside analogues and oligonucleotide derivative comprising nucleotide analogue thereof
US7427672B2 (en) 2003-08-28 2008-09-23 Takeshi Imanishi Artificial nucleic acids of n-o bond crosslinkage type
WO2012029870A1 (ja) * 2010-08-31 2012-03-08 国立大学法人大阪大学 オリゴヌクレオチド、およびオリゴヌクレオチドを有効成分として含有する脂質異常症治療剤

Also Published As

Publication number Publication date
EP2495248B1 (en) 2017-01-11
EP2495248A4 (en) 2013-10-16
CN102596983A (zh) 2012-07-18
US8541562B2 (en) 2013-09-24
EP2495248A1 (en) 2012-09-05
WO2011052436A1 (ja) 2011-05-05
JP5669073B2 (ja) 2015-02-12
CA2778171A1 (en) 2011-05-05
AU2010312751B2 (en) 2014-07-24
JPWO2011052436A1 (ja) 2013-03-21
US20120208991A1 (en) 2012-08-16
CN102596983B (zh) 2016-06-15
AU2010312751A1 (en) 2012-06-14
JP2014043462A (ja) 2014-03-13

Similar Documents

Publication Publication Date Title
CA2778171C (en) Bridged artificial nucleoside and nucleotide
US9611479B2 (en) Crosslinked nucleoside and nucleotide
JP6562517B2 (ja) 架橋型ヌクレオシドおよびヌクレオチド
US7427672B2 (en) Artificial nucleic acids of n-o bond crosslinkage type
US12398171B2 (en) 5′-modified nucleoside and nucleotide using same
JP7438546B2 (ja) ５’位修飾ヌクレオシドおよびそれを用いたヌクレオチド
WO2022004388A1 (ja) ５'位修飾ヌクレオシドおよびそれを用いたヌクレオチド
JP7650412B2 (ja) ５′位修飾ヌクレオシドおよびそれを用いたヌクレオチド
JP7751302B2 (ja) 架橋型ヌクレオシドおよびヌクレオチド
JP7709690B2 (ja) 架橋型ヌクレオシドおよびそれを用いたヌクレオチド
JP4255227B2 (ja) Ｎ３’−ｐ５’結合を有する２’，４’−ｂｎａオリゴヌクレオチド
WO2024101446A1 (ja) 架橋部にグアニジノ構造を有する修飾ヌクレオシドおよびそれを用いたオリゴヌクレオチドの製造方法
CN118946575A (zh) 5'位修饰核苷和使用其的核苷酸

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20151019